Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the AlloStim™ infusion results in the activation of memory T-cells, causing them to leave the patient's circulation and to migrate to the areas of the body where the malignant tumors are located. Prior to the intravenous infusion of AlloStimTM, a sample of blood is taken from each study patient. Another blood sample is drawn 24 to 48 hours after the infusion. Dr. Michael Har-Noy says that these patient blood samples will be analysed in order to verify that the patient's memory cells have left the patient's circulation. The intravenous dose of AlloStim™ activates the patient's immune system, which then can kill the cancer cells. Dr. Michael Har-Noy adds that the intravenous AlloStimTM also provides another fresh source of tumor antigens for that can be processed by the patient's dendritic cells. Tumor-specific and foreign antigen-specific memory cells of the patient's immune system travel to the tumor sites and create an extremely inflammatory microenvironment. Dr. Michael Har-Noy says once this inflammatory microenvironment is established, the patient's natural immune processes then cascade to generate even more circulating tumor-specific memory T-cells.
Additionally, says Dr. Michael Har-Noy, the patient's immune system perceives the intravenous AlloStim™ infusion as a massive infection by foreign cellular material. This perception precipitates a powerful rejection response that results in the development of a 'cytokine storm'. This cytokine storm then maintains a highly inflammatory immune environment, often for several months. Dr. Michael Har-Noy adds that this inflammatory environment can disable a tumor's immune avoidance mechanism and can switch off suppressor cells which tend to stop tumor destruction by the patient's immune system. Dr. Michael Har-Noy concludes by saying that this environment created by the AlloStimTM is ideal for the patient's immune system to eliminate malignancies or to dramatically slow their growth.
Readers can find further information about Dr. Michael Har-Noy's phase I/II CRCL-AlloVaxTM protocol and his Compassionate Use program in Bangkok, Thailand at www.immunocare.net .